Online inquiry

IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11446MR)

This product GTTS-WQ11446MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets NT5E gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001204813.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4907
UniProt ID P21589
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-NT5E, MEDI-9447(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11446MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8179MR IVTScrip™ mRNA-Anti-FCGRT, HL161(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA HL161
GTTS-WQ15930MR IVTScrip™ mRNA-Anti-Felcat NGF, ZTS-00084768(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ZTS-00084768
GTTS-WQ12062MR IVTScrip™ mRNA-Anti-CD19, MOR-00208(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA MOR-00208
GTTS-WQ10015MR IVTScrip™ mRNA-Anti-FGF23, KRN-23(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA KRN-23
GTTS-WQ5980MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ1238MR IVTScrip™ mRNA-Anti-DLL4&VEGFA, ABT-165(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ABT-165
GTTS-WQ3998MR IVTScrip™ mRNA-Anti-PDCD1, BGB-A317(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BGB-A317
GTTS-WQ146MR IVTScrip™ mRNA-Anti-CA9, 124I_WX-G250(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA 124I_WX-G250
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW